{'fraction_non_alphanumeric': 0.02564102564102564, 'fraction_numerical': 0.015384615384615385, 'mean_word_length': 5.684931506849315, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Evaluation of the efficacy of cisplatin-based chemotherapy in epithelial ovarian cancer; comparison with treatments employed before the cisplatin era].

Seventy-five patients with epithelial ovarian cancers received cisplatin-based chemotherapy as a post-surgical treatment in the 1980s. In the 1970s, fifty-eight patients received various treatments without cisplatin, which included radiotherapy, chemotherapy and their combination. In the patients with stage III disease, cisplatin-based chemotherapy achieved a median survival of 24 months, whereas other treatments employed in the 1970s achieved a median survival of 8 months. In the patients with early disease, however, cisplatin-based chemotherapy did not improve the survival. Since it is clear that cisplatin-based chemotherapy achieved an improved survival in the treatment of advanced epithelial ovarian cancer, it is concluded that this therapy is worth continuing until a more effective treatment is available.